Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.
about
Current perspectives in NSAID-induced gastropathyCurrent approaches to prevent NSAID-induced gastropathy--COX selectivity and beyondAbsence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole.Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.Efficacy of esomeprazole in treating acid-related diseases in Japanese populationsPharmacokinetics and pharmacodynamics of the proton pump inhibitors.Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers.A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD).Esomeprazole: a proton pump inhibitor.Esomeprazole: potent acid suppression in the treatment of acid-related disorders.Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparisonEsomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial.Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.Acid control with esomeprazole and lansoprazole: a comparative dose-response study.A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.
P2860
Q26827673-478D5A59-B0E1-409B-9F6B-225337B391F7Q28210656-E6AEC0F0-E543-4650-8067-14563F7BEA12Q33338273-D870899A-7CDF-4402-8E35-148B784C5213Q35010979-1C21412A-D00A-4E26-AEDE-AA56D76D2AF7Q35987201-77D6C631-0A0F-4471-8B1F-D9DA1A3467BAQ36542670-73C71B9C-A5A1-4E9B-9C0C-7AC6D985250FQ36808048-4EF1A054-0971-40E8-8222-B078D00884EEQ37160360-E84B0B5E-6C5B-4DA5-9D83-34D41266AB85Q37390644-16BFCB1B-BB4C-4927-B9A0-77082B6112BCQ37755220-229FECBB-8FD3-4B64-B771-FCFD4FFD2378Q39014361-1AA62120-4A44-4AEB-9422-4E788F50749BQ39349036-196AA827-D047-4904-A640-778B8FC7B4BDQ41634946-BAF10B69-6924-457C-A35F-950B79CA4699Q42613192-F5EB6D01-8B98-459B-8162-DCA2CB744ABDQ42662159-6ADE1C0F-1591-4377-9A0F-6773934F07C0Q46424960-987A8F26-9C78-4F38-9F08-492E7EF8A140Q46901259-E020D415-6B95-4727-97E6-F64046DE55B8Q48099127-76F5CAE7-EE8F-4208-85C7-CE87FD7630D8Q51609254-E2C990D5-8071-491D-8DF3-699222BF007EQ51622395-89E3E028-0EBF-4A34-8C66-DF5122D3CCCAQ55280841-2392BE17-4E26-4B36-B535-BBEB115F1403
P2860
Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Esomeprazole 40 mg provides im ...... e 20 mg in healthy volunteers.
@en
Esomeprazole 40 mg provides im ...... e 20 mg in healthy volunteers.
@nl
type
label
Esomeprazole 40 mg provides im ...... e 20 mg in healthy volunteers.
@en
Esomeprazole 40 mg provides im ...... e 20 mg in healthy volunteers.
@nl
prefLabel
Esomeprazole 40 mg provides im ...... e 20 mg in healthy volunteers.
@en
Esomeprazole 40 mg provides im ...... e 20 mg in healthy volunteers.
@nl
P2093
P356
P1433
P1476
Esomeprazole 40 mg provides im ...... e 20 mg in healthy volunteers.
@en
P2093
Catharina Nilsson-Pieschl
Clive H Wilder-Smith
Kerstin Röhss
Lars Nyman
Ola Junghard
P304
P356
10.1159/000075697
P577
2003-12-19T00:00:00Z